Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

This trial is going to evaluate tumor control and quality of life in patients with prostate cancer treated with radiotherapy or cryoablation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital
• Collaborators: Peking University First Hospital; Shandong Cancer Hospital and Institute; Shanghai Jiao Tong University School of Medicine; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; The Third Xiangya Hospital of Central South University; Tianjin First Central Hospital; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Treatments: Bicalutamide; Hormones; Prolactin Release-Inhibiting Factors

Criteria

Inclusion Criteria:

• Prostate adenocarcinoma, T3aN0M0, T3bN0M0

• Previously untreated disease or undergone endocrine therapy without reaching to castration resistant prostate cancer

• Survival ≥ 12 months

• WHO performance status 0-2

• white blood cell ≥ 3.5 ×10*9/L

• Platelets ≥ 5×10*9/L

• Hemoglobin ≥ 10 g/dL

Exclusion Criteria:

• History of malignant disease

• History of coronary artery disease

• Uncontrolled infection

• Other concurrent severe or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes mellitus, uncontrolled cardiac disease, uncontrolled hypertension, congestive cardiac failure, ventricular arrhythmias, active ischemic heart disease, myocardial infarction within the past six months, chronic liver or renal disease, and active upper gastrointestinal tract ulceration)

• Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study treatment and follow-up schedule